Inclusion Criteria:

• Patients with elevated detrusor Leak Point Pressure of neuropathic etiology and with hydronephrosis grade 1, 2 or 3

Exclusion Criteria:

• Hydronephrosis of non-neuropathic etiology
• Patients who had an urological surgery in the last 4 months prior to the study
• Patients who have undergone urethral dilatation in the last 3 months prior to the baseline urodynamic assessment
• Patients who have received alpha-blocker therapy in the last 4 weeks prior to the baseline urodynamic assessment
• Patients who have received any detrusor injections of botulinum toxin in the last 6 months
• Patients with urological diseases/conditions other than functional bladder obstruction of neuropathic etiology that can lead to upper urinary tract dilatation (e.g., bladder anomalies, ureterocele)
• History of intolerance to alpha-blocker therapy
• Orthostatic hypotension
• History of risk factors for Torsade de pointes (e.g., family history of Long QT Syndrome)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.